NYSE:HQLTekla Life Sciences Investors Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tekla Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.18 +0.07 (+0.46 %) (As of 04/7/2020 04:00 PM ET) Add Compare Share Today's Range$15.12Now: $15.18▼$15.6050-Day Range$12.22MA: $15.26▼$17.9952-Week Range$11.45Now: $15.18▼$18.00Volume142,500 shsAverage Volume130,413 shsMarket Capitalization$345.44 millionP/E RatioN/ADividend Yield9.66%Beta1.24 ProfileAdvanced ChartDividendFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Tekla Life Sciences Investors. Previous Next 2.6 Community Rank Outperform VotesTekla Life Sciences Investors has received 93 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTekla Life Sciences Investors has received 89 “underperform” votes. (Add your “underperform” vote.)Community SentimentTekla Life Sciences Investors has received 51.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tekla Life Sciences Investors and other stocks. Vote “Outperform” if you believe HQL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HQL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend LeadershipTekla Life Sciences Investors is a leading dividend payer. It pays a dividend yield of 9.66%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTekla Life Sciences Investors does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tekla Life Sciences Investors insiders have bought more of their company's stock than they have sold. Specifically, they have bought $110,141.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Tekla Life Sciences Investors is held by insiders.Percentage Held by InstitutionsOnly 16.46% of the stock of Tekla Life Sciences Investors is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Investment offices, not elsewhere classified Sub-IndustryN/A SectorFinance Current SymbolNYSE:HQL Previous Symbol CUSIPN/A CIK884121 Webhttp://www.teklacap.com/ Phone617-772-8500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares22,756,000Market Cap$345.44 million Next Earnings DateN/A OptionableNot Optionable Receive HQL News and Ratings via Email Sign-up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. HQL Rates by TradingView Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions How has Tekla Life Sciences Investors' stock been impacted by COVID-19 (Coronavirus)? Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HQL stock has increased by 2.2% and is now trading at $15.18. View which stocks have been mosted impacted by Coronavirus. How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors? Tekla Life Sciences Investors announced a quarterly dividend on Wednesday, February 19th. Stockholders of record on Friday, February 28th will be given a dividend of $0.39 per share on Tuesday, March 31st. This represents a $1.56 dividend on an annualized basis and a yield of 10.28%. The ex-dividend date of this dividend is Thursday, February 27th. This is a boost from Tekla Life Sciences Investors's previous quarterly dividend of $0.37. View Tekla Life Sciences Investors' dividend history. Has Tekla Life Sciences Investors been receiving favorable news coverage? Headlines about HQL stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tekla Life Sciences Investors earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTekla Life Sciences Investors. Are investors shorting Tekla Life Sciences Investors? Tekla Life Sciences Investors saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 4,100 shares, a decrease of 87.3% from the February 27th total of 32,400 shares. Based on an average daily trading volume, of 104,800 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company's shares are sold short. View Tekla Life Sciences Investors' Current Options Chain. Who are some of Tekla Life Sciences Investors' key competitors? Some companies that are related to Tekla Life Sciences Investors include PIMCO Corporate&Income Opportunity Fund (PTY), Gabelli Equity Trust (GAB), Tri-Continental (TY), Boulder Growth & Income Fund (BIF), Liberty All-Star Equity Fund (USA), Hercules Capital (HTGC), Royce Value Trust (RVT), Blackrock Muniyield Insured Fund (MYI), AllianceBernstein Global Hgh Incm Fd (AWF), Tekla Healthcare Investors (HQH), Invesco Van Kampen Munpl Oprtnty Tr (VMO), Templeton Global Income Fund (GIM), PIMCO High Income Fund (PHK), General American Investors (GAM) and Invesco Trust for Investment GradeMncpls (VGM). What other stocks do shareholders of Tekla Life Sciences Investors own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include Enbridge (ENB), Tekla Healthcare Investors (HQH), Gilead Sciences (GILD), AbbVie (ABBV), Apple Hospitality REIT (APLE), Enterprise Products Partners (EPD), Energy Transfer LP Unit (ET), IBM (IBM), Altria Group (MO) and Walgreens Boots Alliance (WBA). Who are Tekla Life Sciences Investors' key executives? Tekla Life Sciences Investors' management team includes the following people: Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 66)Ms. Laura F. Woodward, Principal Financial Officer, Chief Compliance Officer, Sec. and Treasurer (Age 51)Ms. Betty T. Chang, Assistant Treasurer (Age 47) What is Tekla Life Sciences Investors' stock symbol? Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL." How do I buy shares of Tekla Life Sciences Investors? Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tekla Life Sciences Investors' stock price today? One share of HQL stock can currently be purchased for approximately $15.18. How big of a company is Tekla Life Sciences Investors? Tekla Life Sciences Investors has a market capitalization of $345.44 million. View additional information about Tekla Life Sciences Investors. What is Tekla Life Sciences Investors' official website? The official website for Tekla Life Sciences Investors is http://www.teklacap.com/. How can I contact Tekla Life Sciences Investors? Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Compound Interest
